“Modern phenotypic drug discovery is a viable, neoclassic pharma strategy”. J. Med. Chem.55 (10): 4527–38. (May 2012). doi:10.1021/jm201649s. PMID22409666.
“How were new medicines discovered?”. Nat Rev Drug Discov10 (7): 507–19. (July 2011). doi:10.1038/nrd3480. PMID21701501.
Brown, Dean G.; Wobst, Heike J. (2019-07-18). “Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research” (英語). Journal of Medicinal Chemistry63 (5): 1823–1840. doi:10.1021/acs.jmedchem.9b00797. ISSN0022-2623. PMID31268707.
Barrett MJ, Frail DE, ed (2012). “PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates”. Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, NJ: John Wiley & Sons. pp. 253–290. doi:10.1002/9781118274408.ch9. ISBN978-0-470-87827-9
“Exploiting complexity and the robustness of network architecture for drug discovery”. J. Pharmacol. Exp. Ther.325 (1): 1–9. (April 2008). doi:10.1124/jpet.107.131276. PMID18202293.
“A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery”. Metab. Eng.10 (1): 1–9. (January 2008). doi:10.1016/j.ymben.2007.09.003. PMID17962055.
“theraTRACE®: A mechanism unbiased in vivo platform for phenotypic screening and drug repositioning”. Drug Discovery Today: Therapeutic Strategies8 (2): 89–95. (2011). doi:10.1016/j.ddstr.2011.06.002.
Willis, Clinton; Nyffeler, Johanna; Harrill, Joshua (2020-08-01). “Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay” (英語). SLAS DISCOVERY: Advancing the Science of Drug Discovery25 (7): 755–769. doi:10.1177/2472555220928004. ISSN2472-5552. PMID32546035.
“Modern phenotypic drug discovery is a viable, neoclassic pharma strategy”. J. Med. Chem.55 (10): 4527–38. (May 2012). doi:10.1021/jm201649s. PMID22409666.
“How were new medicines discovered?”. Nat Rev Drug Discov10 (7): 507–19. (July 2011). doi:10.1038/nrd3480. PMID21701501.
Brown, Dean G.; Wobst, Heike J. (2019-07-18). “Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research” (英語). Journal of Medicinal Chemistry63 (5): 1823–1840. doi:10.1021/acs.jmedchem.9b00797. ISSN0022-2623. PMID31268707.
“Exploiting complexity and the robustness of network architecture for drug discovery”. J. Pharmacol. Exp. Ther.325 (1): 1–9. (April 2008). doi:10.1124/jpet.107.131276. PMID18202293.
“A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery”. Metab. Eng.10 (1): 1–9. (January 2008). doi:10.1016/j.ymben.2007.09.003. PMID17962055.
Willis, Clinton; Nyffeler, Johanna; Harrill, Joshua (2020-08-01). “Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay” (英語). SLAS DISCOVERY: Advancing the Science of Drug Discovery25 (7): 755–769. doi:10.1177/2472555220928004. ISSN2472-5552. PMID32546035.
Brown, Dean G.; Wobst, Heike J. (2019-07-18). “Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research” (英語). Journal of Medicinal Chemistry63 (5): 1823–1840. doi:10.1021/acs.jmedchem.9b00797. ISSN0022-2623. PMID31268707.
Willis, Clinton; Nyffeler, Johanna; Harrill, Joshua (2020-08-01). “Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay” (英語). SLAS DISCOVERY: Advancing the Science of Drug Discovery25 (7): 755–769. doi:10.1177/2472555220928004. ISSN2472-5552. PMID32546035.
